文献速递妇科

替西罗莫司联合二甲双胍治疗晚期或复发性子宫内膜癌的Ⅰ期研究

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2025-01-08

本研究为单中心Ⅰ期临床试验,纳入40例晚期或复发性子宫内膜癌患者,评估替西罗莫司联合二甲双胍的安全性及疗效。在33例可评估疗效的患者中,客观缓解率为6%(2例部分缓解),疾病稳定13例(39%),临床获益率为39%。结论认为二甲双胍可安全联合替西罗莫司,但疗效有限。

要点

  • 40例晚期或复发性子宫内膜癌患者接受替西罗莫司联合二甲双胍治疗。
  • 33例可评估疗效者中客观缓解率6%,均为部分缓解,临床获益率39%。
  • 常见治疗相关不良事件为高甘油三酯血症、腹泻、黏膜炎、厌食和贫血。

核心结论

  • 在晚期或复发性子宫内膜癌患者中,二甲双胍可安全联合替西罗莫司,疗效有限且未增加安全性顾虑。

研究设计与样本

  • 单中心Ⅰ期临床试验,剂量扩展队列采用Simon Minimax两阶段设计,共纳入40例患者。
  • 临床试验注册号为NCT01529593。

主要发现

  • 40例患者中,32例报告治疗相关不良事件,最常见为高甘油三酯血症14例、腹泻13例、黏膜炎13例、厌食12例、贫血10例。
  • 3级不良事件包括贫血2例、血小板减少2例,以及黏膜炎、乏力、体重下降、低钾血症、低磷血症、天冬氨酸氨基转移酶升高和丙氨酸氨基转移酶升高各1例。
  • 33例可评估疗效患者中,客观缓解2例(6%,均为部分缓解),疾病稳定13例(39%),其中11例稳定≥4个月,临床获益率为39%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecular alterations in the PI3K/AKT and Ras/Raf/MEK/ERK pathways are frequently observed in patients with endometrial cancers. However, mTOR inhibitors, such as temsirolimus, have modest clinical benefits. In addition to inducing metabolic changes in cells, metformin activates AMPK, which in turn inhibits the mTOR pathway. In this phase 1 clinical trial we hypothesized that combining metformin with temsirolimus would potentiate the antitumor activity against advanced or recurrent endometrial cancer. METHODS: The dose-expansion cohort used a Simon Minimax two-stage design. The objectives of the endometrial cancer expansion cohort were to evaluate the clinical tumor response, as indicated by the objective response and clinical benefit rates, as well as an ongoing safety assessment of the combination treatment. RESULTS: Forty patients were enrolled in this study. The most common treatment-related adverse events (reported in 32 patients) were hypertriglyceridemia (n = 14), diarrhea (n = 13), mucositis (n = 13), anorexia (n = 12), and anemia (n = 10). The grade 3 adverse events were 2 instances each of anemia and thrombocytopenia and 1 instance each of mucositis, fatigue, weight loss, hypokalemia, hypophosphatemia, and increased aspartate aminotransferase and alanine transaminase levels. Among the 33 patients evaluable for response, objective response was seen in two (6 %; both partial responses), and 13 (39 %) patients had stable disease, including 11 for ≥4 months, representing a clinical benefit rate of 39 %. CONCLUSIONS: The results of this single-center clinical trial showed that, in patients with advanced or recurrent endometrial cancer, metformin can be safely added to temsirolimus providing limited response without added safety concerns. CLINICAL TRIAL REGISTRATION NUMBER: NCT01529593.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ahmed J, Stephen B, Khawaja MR, et al. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecol Oncol. 2025. PMID: 39787747. doi:10.1016/j.ygyno.2024.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。